drugset / Trial / NCT07044271

A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants

NCT07044271

Phase 1 Completed 120 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.

Timeline

Start
2025-07-11
Primary completion
2025-11-08
Completion
2025-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Olomorasib Small molecule Oral

Indications

No indication recorded.